| Nov 20 |
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
|
| Nov 20 |
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
|
| Nov 18 |
The first MASH drug could open the door for others — including GLP-1s
|
| Nov 15 |
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
|
| Oct 30 |
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
|
| Oct 21 |
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
|
| Oct 15 |
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
|
| Oct 14 |
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
|
| Oct 14 |
Inventiva secures up to $380m for MASH treatment lanifibranor
|
| Oct 14 |
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
|
